Latest Interferon beta-1a Stories
ROCKLAND, Mass., Nov. 26, 2010 /PRNewswire/ -- EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, announced today that the U.S.
EXTON, Pa., Nov. 2, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. has released a syndicated report focused on the management and treatment of multiple sclerosis (MS) in the US.
EAST HANOVER, N.J., Sept.
Recipients voted highest-scoring medical journal ads by over 4,600 MDs MOUNT LAUREL, N.J., Sept. 21 /PRNewswire-USNewswire/ -- The Association of Medical Media (AMM) presented The Doctors' Choice Awards to the highest-scoring medical journal advertisements Thursday, September 16, 2010.
ROCKLAND, Mass. and NEW YORK, Sept. 1 /PRNewswire-FirstCall/ -- EMD Serono, Inc. and Pfizer Inc.
ROCKLAND, Mass., July 28 /PRNewswire/ -- EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced today that the U.S.
EXTON, Pa., April 26 /PRNewswire/ -- BioTrends is pleased to announce the publication of a new syndicated report, TreatmentTrends: Multiple Sclerosis.
WALTHAM, Mass., April 19 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that early lines of therapy for the treatment of multiple sclerosis are dominated by Teva's Copaxone and Biogen Idec's Avonex, an interferon-beta (IFN-beta) agent.
ROCKLAND, Mass., Jan.
EXTON, Pa., Jan. 11 /PRNewswire/ -- BioTrends Research Group, Inc. announces the release of the Wave One LaunchTrends(Â®): EXTAVIA report. The survey was completed by U.S.
- A woman chauffeur.
- A woman who operates an automobile.